-
Fil d’actualités
- EXPLORER
-
Pages
-
Groupes
-
Evènements
-
Reels
-
Blogs
-
Marketplace
-
Financement
-
Offres
-
Emplois
-
Cours
-
Forums
-
Film
-
Jeux
-
Développeurs
-
Récompenses
-
Babarun (BBRN)
-
Collab Influenceurs
-
Procaly
-
Récompenses
-
Événementiels
-
Calculez vos calories
-
Affiliation Matrice 3x9
-
La silver économie
-
Maps Membres
-
Runsound music
-
Affiliation
-
Prêts Immobiliers
© 2026 Babafig
Français
- Connexion
- Babarun (BBRN)
- Collab Influenceurs
- Événementiels
- Affiliation Matrice 3x9
- Appel pour rendez-vous de 15 minutes
- Liste complète des emoticones à copier coller
- Aprann le kreol
- Maps Membres
- Runsound music
- Mentions légales
- A propos
- Conditions générale de vente
- Confidentialité
- Contactez nous
- Centre de support
- Répertoire
Mises à jour récentes
-
The Cell's Uninvited Guest: Mastering the Art of Molecular Breaking and EnteringFor decades, the biggest challenge in medicine wasn't just finding a drug that worked—it was getting that drug to the right "address" without destroying everything else along the way. Traditional chemotherapy, for instance, is often compared to carpet bombing: it kills the enemy, but it also devastates the surrounding city. As we move through 2026, a quiet revolution in Targeted...0 Commentaires 0 Parts 526 Vue 0 AvisConnectez-vous pour aimer, partager et commenter!
-
Exploring B-Cell Isolation Workflows to Enhance Therapeutic Antibody ScreeningIn modern therapeutic antibody development, the ability to isolate naturally paired heavy and light chain antibody sequences from B cells is a decisive factor in generating fully human, high-affinity monoclonal antibodies (mAbs). Researchers now rely on innovative B-cell sorting workflows that combine precision, efficiency, and biological relevance. Among the most widely used strategies are...0 Commentaires 0 Parts 540 Vue 0 Avis
-
When Two Amino Acids Look the Same but Act DifferentlyIn the rapidly evolving field of protein and antibody analysis, achieving exceptional sequence precision is more important than ever. With advances in mass spectrometry and data analytics, the realm of de novo sequencing has experienced pivotal breakthroughs—especially when it comes to the challenge of distinguishing so-called "ambiguous" amino acids. Today we'll explore how...0 Commentaires 0 Parts 441 Vue 0 Avis
-
Inside the Immune Battlefield: How Engineered Viruses Help Win the War on CancerIn the rapidly evolving landscape of cancer immunotherapy, oncolytic virotherapy has emerged as a dynamic force capable of amplifying the immune response against tumors. Once seen merely as a means of direct tumor lysis, oncolytic viruses (OVs) are now recognized for their ability to reshape the tumor microenvironment, recruit immune cells, and enhance the effectiveness of existing therapeutic...0 Commentaires 0 Parts 672 Vue 0 Avis
-
Redesigning the Rules of Drug Discovery Through Protein DegradationThe rise of targeted protein degradation (TPD) has opened a new chapter in modern drug discovery. Unlike traditional inhibitors that merely block protein activity, degraders work by eliminating disease-causing proteins altogether through the ubiquitin–proteasome system. Behind this elegant mechanism lies a delicate balance between three essential components — linkers, ligands, and...0 Commentaires 0 Parts 515 Vue 0 Avis
-
The Quiet Revolution: How AI-Driven Antibody Engineering Is Rewriting Biotherapeutic DiscoveryThe biopharmaceutical industry is going through a silent but profound transformation. While headlines tend to focus on blockbuster drugs or billion-dollar mergers, another movement is gathering momentum beneath the surface—one powered not by laboratory throughput alone, but by algorithmic intelligence. Antibody engineering, once defined by trial-and-error approaches and lengthy...0 Commentaires 0 Parts 671 Vue 0 Avis
-
From RA to Asthma: Preclinical Models Shaping the Future of ImmunotherapyThe pharmaceutical landscape is entering a phase of unprecedented focus on immune-mediated diseases, with research teams racing to develop treatments for conditions ranging from autoimmune disorders to chronic inflammatory diseases. The key to this progress is not just advanced molecular tools—it is also the strategic use of robust preclinical disease models that faithfully recapitulate...0 Commentaires 0 Parts 957 Vue 0 Avis
-
The Rising Demand for High-Potency ADC Payloads: Why the Supply Chain Is Being Reshaped in 2025Antibody–drug conjugates (ADCs) continue to reshape the oncology pipeline, driven by the pursuit of payloads that can deliver stronger potency, improved tumor selectivity, and reduced systemic toxicity. Although more than a decade has passed since the approval of the first ADC, payload development remains one of the fastest-moving components of the field. With growing interest in high-DAR...0 Commentaires 0 Parts 791 Vue 0 Avis
-
Riding the Non-IgG Wave: Why Researchers Are Turning to Alternative ImmunoglobulinsFor years, the life sciences community has focused its attention—and budgets—on IgG antibodies. They were the gold standard for therapeutic development, biomarker screening, and diagnostic innovation. But as biological questions grow more complex and precision medicine becomes increasingly nuanced, a new trend has emerged: a surge of interest in non-IgG antibodies and proteins....0 Commentaires 0 Parts 786 Vue 0 Avis
-
Best Immunoassay Kit Development Technologies for Modern DiagnosticsIn vitro diagnostics (IVD) have become the cornerstone of modern medical decision-making. Among the vast array of analytical technologies, immunoassays stand out for their high specificity, sensitivity, and adaptability. Over the past few decades, continuous technological refinement—from colorimetric to chemiluminescent detection—has redefined how clinicians and researchers...0 Commentaires 0 Parts 932 Vue 0 Avis
-
Two Primates One Goal Transforming Preclinical Success into Clinical RealityTranslational research depends on reliable animal models that can accurately mimic human biology. Among all preclinical options, non-human primates (NHPs) stand out for their close genetic, immunological, and physiological similarity to humans. Two key NHP species—the Cynomolgus Monkey and the Marmoset—have become indispensable in bridging the gap between discovery and clinical...0 Commentaires 0 Parts 741 Vue 0 Avis
-
Bispecific Antibody Platforms and Target-Based Design: The Key to Next-Generation TherapeuticsIn the rapidly evolving field of antibody therapeutics, bispecific antibodies (BsAbs) are gaining momentum thanks to their ability to engage two distinct targets simultaneously. One critical application lies in developing molecules that specifically interfere with receptor-mediated signalling. For example, when a BsAb is engineered for bispecific receptor binding, it can simultaneously target...0 Commentaires 0 Parts 1K Vue 0 Avis
Plus de lecture